Rapport Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The lead program demonstrated strong efficacy and tolerability in focal-onset seizures, with phase III global trials set to begin soon. Strategic partnerships, a robust pipeline, and a long-acting injectable formulation position the company for growth and extended IP protection.
-
RAP-219, a selective TARP gamma-8 AMPA modulator, showed unprecedented efficacy and safety in Phase 2 epilepsy trials, with global Phase 3 studies underway and expansion into bipolar mania and tonic-clonic seizures. A long-acting injectable formulation and strong financial position further differentiate the program.
-
RAP-219 demonstrated strong efficacy and safety in refractory focal-onset seizures, enabling accelerated phase III trials in 2026. Market research supports best-in-class potential, with a multi-billion dollar opportunity and expansion into bipolar mania and pain. Funding extends into 2029, supporting multiple clinical milestones.
-
Rapport Therapeutics presented strong phase 2 results for RAP-219 in focal onset seizures, with plans to start pivotal trials and expand into additional indications, including a first-in-class long-acting injectable. The company highlighted significant market opportunities and a robust pipeline, with key data readouts expected through 2027.
Fiscal Year 2025
-
RAP-219, a precision neuroscience candidate, showed over 70% seizure reduction and strong tolerability in phase II, with pivotal studies planned for 2026 and a long-acting injectable in development. The program targets a large, treatment-resistant epilepsy market and is expanding into bipolar mania.
-
RAP-219, a precision AMPA modulator, showed robust efficacy and tolerability in epilepsy, with phase three trials set to begin by Q3 2026. Expansion into bipolar mania and other indications is underway, supported by strong financials and a multi-billion dollar market outlook.
-
Phase 2 data for RAP-219 in drug-resistant focal epilepsy showed robust efficacy and a favorable safety profile, supporting broad clinical adoption and a significant market opportunity. Two Phase 3 trials are planned for 2026, with strong financial backing and expanded development into bipolar mania and pain.
-
RAP-219 demonstrated robust efficacy and favorable tolerability in a Phase 2A trial for drug-resistant focal onset seizures, with rapid onset and high seizure freedom rates. Plans are underway for Phase 3 trials and further development, including a long-acting injectable formulation.
-
RAP-219's phase IIA epilepsy trial is fully enrolled, with data expected in September. The study uses an innovative EEG biomarker design for efficient, objective efficacy assessment, and success could lead to rapid phase III advancement. Cash reserves support operations through 2026.
-
The session highlighted a precision neuroscience platform with RAP-219 as a differentiated anti-seizure candidate, showing strong preclinical and early clinical safety and efficacy. A fully enrolled phase IIA study in refractory epilepsy uses objective EEG biomarkers, with top line data expected in September.
-
RAP-219, a precision AMPA modulator, is advancing in a fully enrolled phase 2A trial for refractory focal epilepsy, with top-line results expected in September 2024. The program targets a best-in-class profile with strong safety, once-daily dosing, and plans for rapid phase 3 progression if successful.
-
Precision neuroscience program RAP-219 targets focal epilepsy with a novel, highly selective mechanism, supported by robust preclinical and phase I data. An innovative phase II trial using objective electrographic biomarkers aims to predict phase III success, with data expected in Q3.
-
Leadership outlined a precision neuroscience strategy leveraging receptor-associated proteins, with RAP-219 showing strong preclinical and early clinical promise in epilepsy. Innovative trial design using RNS devices enables rapid, objective efficacy assessment, with top-line data expected in Q3 and plans for expansion into bipolar mania and neuropathic pain.
-
The discussion highlighted a precision neuroscience approach leveraging receptor-associated proteins, with RAP-219 in phase IIa for refractory focal epilepsy. The study uses objective long episode biomarkers, aiming for faster, more reliable results, and plans expansion into bipolar and pain indications.
-
RAP-219 is advancing in a phase 2A epilepsy study with data expected in Q3, leveraging a novel mechanism and innovative trial design. Additional programs in bipolar and neuropathic pain are planned, with a strong financial position supporting development through 2026.
Fiscal Year 2024
-
Rapport is advancing RAP-219, a precision AMPA modulator, in focal epilepsy with a novel biomarker-driven phase 2 trial. Ongoing studies aim to confirm receptor occupancy and inform expansion into neuropathic pain and bipolar mania, with key data expected in early 2025.
-
Precision neuroscience pipeline targets epilepsy, pain, and bipolar disorder, with RAP-219 as lead. Phase IIa trial in focal epilepsy uses a validated biomarker, with data expected mid-2025. Cash runway extends through 2026, supporting further development.
-
The company is advancing RAP-219, a precision AMPA modulator for focal epilepsy, with strong preclinical and early clinical data supporting efficacy and safety. Proof-of-concept data are expected mid-2025, with expansion into neuropathic pain and bipolar disorder enabled by a recent IPO.